Aktuellt
SENASTE
Redeye returns with a more in-depth view of the case changes following the inconclusive study results from the FORTIFY trial. We argue that the longer-term prospects of the case remain relatively intact, as we believe BONESUPPORT will recommence its US launch of CERAMENT G for the trauma indication, after anticipated FDA discussions granting a De Novo application. The inconclusive study results are not a “curtains-down” event, which we soon expect the market to realize.
LÄS MER
